NetworkNewsBreaks – Cascadian Therapeutics, Inc. (NASDAQ: CASC) Reports Positive Regulatory Update for Tucatinib in Europe Following EMA Discussion
Cascadian Therapeutics (NASDAQ: CASC) this morning reported a positive outcome from recent discussions with the European Medicines Agency (EMA) regarding the development of the company’s investigational medicine for the treatment of HER2-positive metastatic breast cancer, tucatinib. The company has received validating news that if the ongoing pivotal trial of tucatinib known as HER2CLIMB demonstrates positive results, it could serve as a single registrational trial for submission of a Marketing Authorization Application (MAA) to the EMA and potential marketing approval. Cascadian received a similar confirmation from the FDA last year. “This is an important milestone for the company. We had anticipated…







